
No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients
How to Cite
OrthoEvidence. No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients. ACE Report. 2021;20(1):4. Available from: https://myorthoevidence.com/AceReport/Report/13409
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
N Engl J Med. 2021 Mar 11;384(10): 905-914.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, s...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!


Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.